<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27383586</article-id>
<article-id pub-id-type="pmc">4938857</article-id>
<article-id pub-id-type="publisher-id">1069-16</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.1069-16.2016</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group>
<subject>Development/Plasticity/Repair</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes <italic>In Vivo</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Higashimori</surname>
<given-names>Haruki</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5212-5249</contrib-id>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schin</surname>
<given-names>Christina S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chiang</surname>
<given-names>Ming Sum R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morel</surname>
<given-names>Lydie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shoneye</surname>
<given-names>Temitope A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nelson</surname>
<given-names>David L.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Yongjie</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0318-8224</contrib-id>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Tufts University, Department of Neuroscience, Boston, Massachusetts 02111, </aff>
<aff id="aff2"><sup>2</sup>Department of Molecular and Human Genetics, Jan and Dan Duncan Neurological Research Institute, Baylor College of Medicine, Houston, Texas 77030, and </aff>
<aff id="aff3"><sup>3</sup>Tufts University, Sackler School of Biomedical Sciences, Boston, Massachusetts 02111</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Yongjie Yang,
<addr-line>Tufts University, Department of Neuroscience, 136 Harrison Avenue, Boston, MA 02111.</addr-line><email>yongjie.yang@tufts.edu</email></corresp>
<fn fn-type="con">
<p>Author contributions: H.H. and Y.Y. designed research; H.H., C.S.S., M.S.R.C., L.M., and T.A.S. performed research; D.L.N. contributed unpublished reagents/analytic tools; H.H., C.S.S., M.S.R.C., and Y.Y. analyzed data; Y.Y. wrote the paper.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>6</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>6</day>
<month>1</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>36</volume>
<issue>27</issue>
<fpage>7079</fpage>
<lpage>7094</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>3</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>4</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>5</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2016 the authors 0270-6474/16/367080-16$15.00/0</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="zns02716007079.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>How the loss of fragile X mental retardation protein (FMRP) in different brain cell types, especially in non-neuron glial cells, induces fragile X syndrome (FXS) phenotypes has just begun to be understood. In the current study, we generated inducible astrocyte-specific <italic>Fmr1</italic> conditional knock-out mice (i-astro-<italic>Fmr1</italic>-cKO) and restoration mice (i-astro-<italic>Fmr1</italic>-cON) to study the <italic>in vivo</italic> modulation of FXS synaptic phenotypes by astroglial FMRP. We found that functional expression of glutamate transporter GLT1 is 40% decreased in i-astro-<italic>Fmr1</italic>-cKO somatosensory cortical astrocytes <italic>in vivo</italic>, which can be fully rescued by the selective re-expression of FMRP in astrocytes in i-astro-<italic>Fmr1</italic>-cON mice. Although the selective loss of astroglial FMRP only modestly increases spine density and length in cortical pyramidal neurons, selective re-expression of FMRP in astrocytes significantly attenuates abnormal spine morphology in these neurons of i-astro-<italic>Fmr1</italic>-cON mice. Moreover, we found that basal protein synthesis levels and immunoreactivity of phosphorylated S6 ribosomal protein (p-s6P) is significantly increased in i-astro-<italic>Fmr1</italic>-cKO mice, while the enhanced cortical protein synthesis observed in <italic>Fmr1</italic> KO mice is mitigated in i-astro-<italic>Fmr1</italic>-cON mice. Furthermore, ceftriaxone-mediated upregulation of surface GLT1 expression restores functional glutamate uptake and attenuates enhanced neuronal excitability in <italic>Fmr1</italic> KO mice. In particular, ceftriaxone significantly decreases the growth rate of abnormally accelerated body weight and completely corrects spine abnormality in <italic>Fmr1</italic> KO mice. Together, these results show that the selective loss of astroglial FMRP contributes to cortical synaptic deficits in FXS, presumably through dysregulated astroglial glutamate transporter GLT1 and impaired glutamate uptake. These results suggest the involvement of astrocyte-mediated mechanisms in the pathogenesis of FXS.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> Previous studies to understand how the loss of function of fragile X mental retardation protein (FMRP) causes fragile X syndrome (FXS) have largely focused on neurons; whether the selective loss of astroglial FMRP <italic>in vivo</italic> alters astrocyte functions and contributes to the pathogenesis of FXS remain essentially unknown. This has become a long-standing unanswered question in the fragile X field, which is also relevant to autism pathogenesis. Our current study generated astrocyte-specific <italic>Fmr1</italic> conditional knock-out and restoration mice, and provided compelling evidence that the selective loss of astroglial FMRP contributes to cortical synaptic deficits in FXS, likely through the dysregulated astroglial glutamate transporter GLT1 expression and impaired glutamate uptake. These results demonstrate previously undescribed astrocyte-mediated mechanisms in the pathogenesis of FXS.</p>
</abstract>
<kwd-group>
<kwd>astrocyte</kwd>
<kwd>autism</kwd>
<kwd>FMRP</kwd>
<kwd>fragile X</kwd>
<kwd>glutamate transporter</kwd>
<kwd>protein synthesis</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>twij</meta-name>
<meta-value>true</meta-value>
</custom-meta>
<custom-meta>
<meta-name>special-property</meta-name>
<meta-value>cellular</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>